Literature DB >> 21849926

Gastroesophageal reflux studies using milk in infants and children--the need for multiple views.

Saleh Othman1.   

Abstract

The aim of this study was to assess the value of multiple acquisitions in detecting position-related gastroesophageal reflux (GER). We retrospectively reviewed milk scans of 105 patients with suspected GER and possible lung complications. After 2 h of fasting, 11.4 MBq Tc-99m-sulfur colloid was given to the patient orally along with formula or milk (infants). Without sedation in most patients, serial images (30 s each for 15 frames=8 min) were acquired in the supine, prone, right-side down, and left-side down positions. If reflux was detected in one position, before proceeding to the next position the patient was given water or milk to clear the esophagus.The study was considered positive if the activity reappeared in the esophagus. Anterior and posterior chest images were obtained after a delay of 2-4 h to detect any pulmonary aspiration. A total of 59 patients (56.2%) tested negatively for GER in all four positions and also showed a negative delayed scan for pulmonary aspiration. In contrast, 46 patients tested positively for GER in variable positions (prone=4, supine=6, left-side down=3, right-side down=12, and in more than one position=21, of which six included the supine position). The percentage yield of a positive GER position-related technique was three-fold that of conventional single supine position. These results may aid a better understanding of the pathophysiology of the disease and the design of preventive and therapeutic measures.

Entities:  

Mesh:

Year:  2011        PMID: 21849926     DOI: 10.1097/MNM.0b013e32834a0b0d

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  1 in total

1.  Evaluation of technetium-99m metastable nanocolloid as an imaging agent for performing milk scans.

Authors:  Osayande Evbuomwan; Jaleelat Momodu; Khushica Purbhoo; Mboyo D T Vangu
Journal:  Nucl Med Commun       Date:  2019-01       Impact factor: 1.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.